6 Needs context
Approximately 60% to 70% of people taking prescription GLP-1 drugs experience gastrointestinal side effects, and about 4% experience very serious side effects.
"when you look at the data, I mean, a lot of people, 60-70% of people have some GI side effects. 4% have very serious side effects." (said at 0:01:47)
Data from Phase 3 randomized controlled trials of GLP-1 receptor agonists (such as semaglutide 2.4 mg in the STEP trial program) show that gastrointestinal adverse events occur in approximately 60% to 70% or more of participants, most commonly nausea (43.9%), diarrhea (29.7%), vomiting (24.5%), and constipation (24.2%). However, 99.5% of these gastrointestinal adverse events were non-serious and 98.1% were mild-to-moderate in severity. The ~4% figure cited as 'very serious side effects' closely matches the proportion of participants who permanently discontinued treatment due to gastrointestinal adverse events (4.3%), rather than the rate of severe or life-threatening adverse events.
A randomized controlled trial comparing bariatric surgery to a dietary intervention replicating the post-surgery diet in patients with diabetes found no difference in weight loss or metabolic markers between the groups.
"I saw a study once on bariatric surgery where they did a randomized control trial. Essentially, it was a group that got bariatric surgery with diabetes, and then another group that had the same dietary intervention as if you'd already had the surgery. In other words, they gave them the same food, the diet that the bariatric surgery patients had to eat, essentially. And there was absolutely no difference in any of the weight loss, metabolic markers, anything else." (said at 0:18:09)
A landmark clinical study published in the New England Journal of Medicine (Yoshino et al., 2020) compared 22 patients with obesity and type 2 diabetes undergoing Roux-en-Y gastric bypass or a low-calorie diet intervention. The study found that metabolic improvements—including hepatic insulin sensitivity, muscle insulin sensitivity, beta-cell function, and 24-hour glucose profiles—were essentially identical between groups, concluding that the metabolic benefits of gastric bypass are mediated by weight loss rather than surgery-specific mechanisms. However, the lack of difference in weight loss was a deliberate feature of the experimental design (groups were matched to achieve ~18% weight loss to isolate weight-independent effects), rather than an incidental outcome of providing equivalent diets.
A study found a 45% increase in the incidence of small intestinal bacterial overgrowth (SIBO) among GLP-1 receptor agonist users.
"And I read one study, it was like a 45% increase in SIBO with GLP-1 users." (said at 0:52:20)
Large observational evidence indicates that GLP-1 receptor agonists and dual GLP-1/GIP agonists are associated with an increased risk of incident small intestinal bacterial overgrowth (SIBO), likely due to delayed gastrointestinal motility. However, the specific 45% figure does not match the published literature. In a global propensity score-matched cohort analysis of over 430,000 patients, GLP-1 RA users had more than double the short-term hazard of SIBO compared to other second-line type 2 diabetes medications (HR 2.14, a ~114% relative increase), though the absolute incidence remained extremely low (0.177 vs 0.083 per 1,000 patient-years).
Studies show that women taking GLP-1 receptor agonists like tirzepatide achieve greater weight loss when also receiving hormone replacement therapy (HRT).
"We've got one study—it was small, but we've got one study looking at tirzepatide and GLP-1s, and they did better when they were on HRT. They had more appreciable weight loss." (said at 0:57:15)
Preliminary observational and conference data (such as a small retrospective cohort study from the Mayo Clinic presented in 2024 evaluating semaglutide in postmenopausal women with or without menopausal hormone therapy) reported greater percentage total body weight loss in women co-prescribed hormone replacement therapy. Mechanistic and theoretical literature also proposes synergistic effects between sex steroids and GLP-1 receptor agonists (e.g., PMID 31443779). However, randomized controlled trials specifically testing this combination are lacking, and major clinical trial subanalyses of medications like tirzepatide (such as SURMOUNT, PMID 40074721) have primarily evaluated weight loss across reproductive stages rather than comparing outcomes based on concurrent hormone replacement therapy.
- context: The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonis… (Medical hypotheses 2019) · cited 2x in the literature
"Recent research has found potential therapeutic effect of combination therapies with sex hormones and GLP-1 agonists in reducing body weight. Based on the aforementioned, we hypothesize that there is a possible synergistic effect of GLP-1 agonists and sex hormones on body mass reduction in patients with type 2 diabetes." (abstract, results, passage verified)
pubmedfull study (doi) - context: Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc … (Obesity (Silver Spring, Md.) 2025) · cited 18x in the literature
"In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause… (Cureus 2026)
"Across the selected studies, GLP-1RAs were associated with increased weight loss and a decrease in central adiposity in menopausal and postmenopausal women." (abstract, results, passage verified)
pubmedfull study (doi)
A paper published in the Journal of Diabetes in late 2024 or 2025 discussed individualized onboarding of GLP-1s and provided a chart on dosing adjustments using the click pen method.
"A paper came out in the Journal of Diabetes in 2025, I think, or end of '24, talking about microdosing GLP-1s, but the way that they talked about it was—it was published, it was an opinion paper, it wasn't a study, but the way they talked about it was individualized onboarding... and this Journal of Diabetes paper did give you a whole chart on—and I know that's available in Europe—a whole chart on how to change your dose or your patient's dose based on how many clicks you do." (said at 1:01:06)
The speaker accurately describes the publication's topic, format, and timing, but slightly misnames the venue. In early 2025, a commentary letter titled "One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens" by Komé et al. was published in Diabetes Care (not the Journal of Diabetes). The piece is a letter/opinion article rather than an interventional trial, discussing the clinical practice of 'microdosing' and individualizing GLP-1 receptor agonist initiation/titration by counting clicks on multidose pens.
Two recent observational studies show that GLP-1 receptor agonists are correlated with potential prevention or reduced risk of breast cancer.
"Cancer. I think it's really exciting to see—there's two studies that came out recently showing potential prevention with—and it's not causative, it's correlative from what we have. It's observational, but breast cancer." (said at 1:14:38)
The speaker accurately emphasizes that the available evidence is observational and correlative rather than causative. Recent real-world observational studies have evaluated GLP-1 receptor agonist use and breast cancer risk, with mixed findings. A large 2026 retrospective cohort study of women undergoing breast imaging found that GLP-1 agonist exposure was associated with a significant reduction in breast cancer incidence (propensity-matched OR 0.695, 95% CI 0.590–0.819). Conversely, another large nationwide 2024 observational study in patients with type 2 diabetes found that while GLP-1 receptor agonists were associated with reduced risk for 10 of 13 obesity-associated cancers, they were not associated with a statistically significant reduction in postmenopausal breast cancer risk.
- context: Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients Wi… (JAMA network open 2024) · cited 285x in the literature
"GLP-1RAs were not associated with a reduced risk of postmenopausal breast cancer or thyroid cancer." (abstract, results, passage verified)
pubmedfull study (doi) - supports: GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in W… (JCO oncology practice 2026) · cited 4x in the literature
"In the matched logistic regression (30,528 observations; 600 cancer cases), GLP-1 exposure was associated with a lower breast cancer incidence (OR, 0.695 [95% CI, 0.590 to 0.819]; P < .0001). In this large observational study of women undergoing breast imaging at a major academic center and affiliated sites, GLP-1 treatment was associated with a lower incidence of breast cancer, independent of age, race, ethnicity, BMI, breast density, and diabetes." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.